RecruitingPhase 2NCT05617859

Lenvatinib for Advanced Bone and Soft Tissue Sarcoma

A Multicenter, Open, One-arm Phase II Study of Ranvastinib Mesylate Capsules in the Treatment of Advanced Bone and Soft Tissue Sarcoma After Chemotherapy Failure

Sponsor

Henan Cancer Hospital

Enrollment

60 participants

Start Date

Apr 30, 2023

Study Type

INTERVENTIONAL

Conditions

Sexuality Effectiveness

Summary

A total of 60 patients with metastatic/surgically unresectable bone and soft tissue sarcomas who had previously received multi-target TKI therapy and failed were enrolled to evaluate the efficacy and safety.

Eligibility

Min Age: 10 YearsMax Age: 70 Years

Plain Language Summary

Simplified for easier understanding

This study is testing lenvatinib — a pill that blocks blood vessel growth in tumors — in people with advanced bone and soft tissue sarcomas (cancers of the body's connective tissues) that have already been treated with other targeted drugs. **You may be eligible if...** - You are between 10 and 70 years old with bone or soft tissue sarcoma that has spread or cannot be surgically removed - You have previously been treated with apatinib or anlotinib, and your disease progressed or you no longer respond to other therapies - You have at least one measurable tumor on imaging - Your blood counts and organ function meet required levels - Your life expectancy is at least 3 months **You may NOT be eligible if...** - You have not received prior treatment with relevant targeted drugs - Your blood counts, liver, kidney, or heart function are outside acceptable ranges - You have uncontrolled high blood pressure or bleeding problems - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGLenvatinib mesylate capsule

Lenvatinib mesylate capsule, 8mg (body weight ≤60kg) or 12mg (body weight \>60kg), orally, once daily. Take the medicine about half an hour after meals (the time of taking the medicine should be the same as possible every day) and take it with warm water.